Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial

MLA

Sculier, Delphine, and Gilles Wandeler. “Efficacy and Safety of Dolutegravir plus Emtricitabine versus Standard ART for the Maintenance of HIV-1 Suppression: 48-Week Results of the Factorial, Randomized, Non-Inferiority SIMPL’HIV Trial.” PLoS Medicine, vol. 17, no. 11, Nov. 2020, p. e1003421. EBSCOhost, https://doi.org/10.1371/journal.pmed.1003421.

APA

Sculier, D., & Wandeler, G. (2020). Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL’HIV trial. PLoS Medicine, 17(11), e1003421. https://doi.org/10.1371/journal.pmed.1003421

Chicago

Sculier, Delphine, and Gilles Wandeler. 2020. “Efficacy and Safety of Dolutegravir plus Emtricitabine versus Standard ART for the Maintenance of HIV-1 Suppression: 48-Week Results of the Factorial, Randomized, Non-Inferiority SIMPL’HIV Trial.” PLoS Medicine 17 (11): e1003421. doi:10.1371/journal.pmed.1003421.